<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly!

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Preclinical Consulting Services

Learn more about how our consulting services can help to support your journey to the clinic.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Lymphoma PDX Models

Identifying robust preclinical models for lymphoma is essential for the development of new therapies targeting this disease. Patient-derived xenograft (PDX) models provide a predictive preclinical model with true representation of the human heterogeneity providing an accurate approach to predicting an agent’s efficacy prior to entering the clinic. The Crown Bioscience lymphoma PDX collection consists of many models, including both primary and metastatic models. More

PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. Crown Bioscience’s HuPrime® PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.
MODEL NUMBER CANCER TYPE CANCER SUBTYPE DESCRIPTION # per page
LY0257 Lymphoma NHL (DLBCL, ABC, MYD88 L265P) Non-Hodgkin's lymphoma (large B cell). IHC results: CD20(+), CD45RO(-), CD3(-), CD15(-), CD79alpha(+), CD30(-), CK(-), CD56(-). CLICK TO VIEW
LY14019 Lymphoma NHL Non-Hodgkin's Lymphoma CLICK TO VIEW
LY2104 Lymphoma EBV transformed lymphoma N/A CLICK TO VIEW
LY2118 Lymphoma EBV transformed lymphoma Gastric cancer, tumor mass: 8cm x 7cm, inflammatory cells infiltrated through body and gastric antrum, Small tumor foci are remained, consistent with the changes after chemotherapy. Regional LN: right cardial LN (0/5), left cardial LN (0/7), LN of vasa brevia (0/2), left gastroepiploic vascular LN (0/2), right gastroepiploic vascular LN (0/1), inferior pyloric LN (0/1), LN of left gastric artery (0/3), LN of hepatic artery in ligamentum hepatoduodenale(0/1). IHC results: CD44(+), Cmet(weak +), EGFR(+), HER2(3+), Ki-67(+50-75%), MMP7(-), P170(-), P27(+50-75%), P53(+>75%), TOPOII(-). CLICK TO VIEW
LY2201 Lymphoma Lymphoma NA CLICK TO VIEW
LY2214 Lymphoma NHL (DLBCL, GCB) Non-Hodgkin lymphoma (large B cell). IHC results: CD3(-), CD45RO(-), CD20(+), CD79 a(+), Ki-67(80%), CD10(-),CD30(-), ALK(-), Bcl-6(-), MUM1(-). CLICK TO VIEW
LY2219 Lymphoma EBV transformed lymphoma gastric adenocarcinoma, signet ring cell carcinoma CLICK TO VIEW
LY2240 Lymphoma EBV transformed lymphoma gastric caner CLICK TO VIEW
LY2264 Lymphoma NHL (DLBCL, ABC, MYD88 L265P) Non-Hodgkin's lymphoma (diffuse large B cell lymphoma). IHC results: CD3(-), CK(-), CD20(+), Vim(+/-), CD79 a(+/-), CD45RO(-), Ki67(80%), CD30(-), HMB45(-), Mart-1(-), Pax-5(+), Bc1-6(+), EMA(-), CK7(-), P63(-), ALK(-), CD10(-). CLICK TO VIEW
LY2266 Lymphoma NHL (B cell, ABC/GCB) Non-Hodgkin's lymphoma (B cell lymphoma with plasma cell differentiation). IHC results: CK(-), CD20(+), CD3(-), CD79 a(+), Ki-67(40%), CD5(-), CyclinD1(-), CD138(+/-), CD56(-), CD10(-), Bc1-6(-), Pax-5(+), MUM1(+/-), CD45RO(-). CLICK TO VIEW
LY2298 Lymphoma B cell lymphoma (ABC/GCB, MYD88 L265P) B cell lymphoma of right forehead. IHC results: CD20(++), CD79a(+), Ki-67(+ 80%), CD56(-), CD3(-), CD45RO(-), NSE(-), GFAP(-), Syn(-), S-100(-). CLICK TO VIEW
LY2301 Lymphoma NHL (DLBCL, ABC) Reactive hyperplasia of lymph node CLICK TO VIEW
LY2310 Lymphoma B cell lymphoma N/A CLICK TO VIEW
LY2318 Lymphoma NHL (DLBCL, GCB) NA for clinical diagnosis info. CLICK TO VIEW
LY2345 Lymphoma NHL (DLBCL, ABC/GCB) Non Hodgkin lymphoma (consider large B cell lymphoma). IHC result: CD3(-), CD45Ro(-), CD20(+), CD79a(+), Pax-5(+), CD5(+/-), CD10(+), BCL-6(-), CyclinD1(-), MUM1(+). CLICK TO VIEW
LY3071 Lymphoma EBV transformed lymphoma Lung: Bronchioloalveolar carcinoma of lung, peripheral type. CLICK TO VIEW
LY3148 Lymphoma Burkitt lymphoma Burkitt lymphoma of parapharynx and paracranium. CLICK TO VIEW
LY3463 Lymphoma B cell lymphoma NA CLICK TO VIEW
LY3604 Lymphoma NHL (DLBCL, ABC/GCB) Diffuse large B cell lymphoma CLICK TO VIEW
LY3654 Lymphoma Follicular lymphoma Posterior peritoneum: follicular lymphoma CLICK TO VIEW
LY3786 Lymphoma NA Left axillary lymph node: malignant lymphoma CLICK TO VIEW
LY6696 Lymphoma NA NA for clinical diagnosis info. CLICK TO VIEW
LY6701 Lymphoma DLBCL, GCB Right lobe of liver: Non-Hodgkin lymphoma, diffuse large B cell lymphoma CLICK TO VIEW
LY6931 Lymphoma ALCL, anaplastic large cell lymphoma ALCL, anaplastic large cell lymphoma CLICK TO VIEW
LY6933 Lymphoma NHL (DLBCL, ABC/GCB) Diffuse large B cell lymphoma, derived from activated b lymphocyte CLICK TO VIEW
LY6934 Lymphoma NHL (DLBCL, ABC/GCB) Diffuse large B cell lymphoma CLICK TO VIEW
LY6938 Lymphoma Lymphoma NA CLICK TO VIEW

Sorry, no posts matched your criteria.

Create Account to View All Model Data

Already Registered? Login